Expression of Foxp3 and interleukin‑7 receptor and clinicopathological characteristics of patients with diffuse large B‑cell lymphoma

Yan, Zhao; Cui, Weigang; Zhi-yin, Feng; Xue, Jing; Abulajiang, Gulinaer; Zhang, Wei

doi:10.3892/ol.2020.11374

Cited by 11 publications

(20 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunohistochemistry staining was scored as described previously blindly by two independent pathologists without knowledge of the patient's clinicopathology and clinical outcome [18,19] . Positive cases were de ned by the presence of intracellular staining with red/brown color in epithelial cells.…”

Section: Evaluation Of Immunostaining Resultsmentioning

confidence: 99%

CILP2 overexpression correlates with tumor progression and poor prognosis in patients with colorectal cancer in the study of The Cancer Genome Atlas (TCGA) and our cohort analysis

Huang

Peng

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Genetic alterations play an important role in the progression of colorectal cancer. Identifying new biomarkers to assess the prognosis of patients with colorectal cancer is critical. Cartilage Intermediate Layer Protein 2 (CILP2) gene, screened from the TCGA database by bioinformatics, may be closely related to the progression of colorectal cancer. CILP2 was barely reported with clinical features of tumors.Materials and methods: Clinical information and RNA-seq data were derived from the TCGA colorectal carcinoma cohort. CILP2 expression at mRNA level was estimated by bioinformatical analysis of TCGA cases. Tissue microarray (TMA) was constructed containing paraffin-embedded 64 pairs of colorectal cancer and matched adjacent normal tissues. The expression at the protein level was detected in 64 pairs of colorectal cancer and matched adjacent normal tissues by immunohistochemical analysis. CILP2 expression level and its clinical value were estimated by bioinformatical analysis with linear and logistic regression. Survival analysis was performed between high and low groups of CILP2 expression by Cox regression analysis, and the P-value was calculated by the log-rank test. Kaplan-Meier curves were tested by the log-rank test.Results: CILP2 was statistically significantly higher expressed in the colorectal cancer tissues when compared with paired adjacent normal tissues in the TCGA cohort (P<0.001) and in the TMA cohort (P=0.001). Also, CILP2 high-expression was strongly correlated with T3/4 stage (P=0.001), N1/2/3 stage (P=0.005), M1 stage (P=0.048), and higher clinical stage (UICC 2010 stage) (P<0.001) in TCGA cohort, and also positively associated with T3/4 stage (P=0.022) and higher clinical stage (UICC 2010 stage) (P=0.03) in TMA cohort. Furthermore, CILP2 overexpression predicted poor prognosis and could be as an independent prognostic factor (P=0.003).Conclusion: We revealed that CILP2 is associated with advanced stages and could play a role as an independent predictor of poor survival in colorectal cancer.

show abstract

Section: Evaluation Of Immunostaining Resultsmentioning

confidence: 99%

CILP2 overexpression correlates with tumor progression and poor prognosis in patients with colorectal cancer in the study of The Cancer Genome Atlas (TCGA) and our cohort analysis

Huang

Peng

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Immunohistochemistry staining was scored as described previously blindly by two independent pathologists without knowledge of the patient's clinicopathology and clinical outcome [17] . Positive cases were defined by the presence of intracellular staining with red/brown color in epithelial cells.…”

Section: Evaluation Of Immunostaining Resultsmentioning

confidence: 99%

CILP2 overexpression predicts poor prognosis in colorectal cancer

Huang

Peng

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Cartilage Intermediate Layer Protein 2 (CILP2), a glycoprotein with mutations associated with abnormal blood lipid concentrations in normal and cardiovascular diseases patients, was barely reported with clinical features of tumors. We evaluated the role of CILP2 among all stages and histology in colorectal cancer (CRC) in the Cancer Genome Altas (TCGA), and furtherly verified using immunohistochemistry assay within human CRC tissues. Materials and methods Clinical information and RNA-seq data were derived from TCGA colorectal carcinoma cohort. CILP2 expression at mRNA level was estimated by bioinformatical analysis of TCGA cases. Tissue microarray (TMA) was constructed containing paraffin-embedded 64 pairs of CRC and matched adjacent normal tissues. The expression at protein level was detected in 64 pairs of CRC and matched adjacent normal tissues by immunohistochemical analysis. CILP2 expression level and its clinical value were estimated by bioinformatical analysis with linear and logistic regression. Survival analysis was performed between high and low groups of CILP2 expression by Cox regression analysis, and P value was calculated by log-rank test. Kaplan-Meier curves were tested by log-rank test. Results CILP2 was significantly higher expressed in the colorectal cancer tissues when compared with paired adjacent normal tissues in TCGA cohort (P < 0.001) and in TMA cohort (P = 0.001). In addition, CILP2 high-expression was strongly correlated with T3/4 stage (P = 0.001), N1/2/3 stage (P = 0.005), M1 stage (P = 0.048), and higher clinical stage (UICC 2010 stage) (P < 0.001) in TCGA cohort, and also positively associated with T3/4 stage (P = 0.022) and higher clinical stage (UICC 2010 stage) (P = 0.03) in TMA cohort. Furthermore, CILP2 overexpression predicted poor prognosis and could be as an independent prognostic factor (P = 0.003). Conclusion We revealed that CILP2 is associated with advanced stages and could play a role as an independent predictor of poor survival in colorectal cancer.

show abstract

“…Immunohistochemistry staining was scored as described previously blindly by two independent pathologists without knowledge of the patient's clinicopathology and clinical outcome [17] . Positive cases were de ned by the presence of intracellular staining with red/brown color in epithelial cells.…”

Section: Evaluation Of Immunostaining Resultsmentioning

confidence: 99%

CILP2 overexpression correlates with tumor progression and predicts poor outcome in patients with colorectal cancer

Huang¹,

Peng²,

Ye³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Genetic alterations play an important role in the progression of colorectal cancer (CRC). Identifying new biomarkers to assess the prognosis of patients with colorectal cancer is critical. Cartilage Intermediate Layer Protein 2 (CILP2) gene, screened from the TCGA database by bioinformatics, may be closely related to the progression of colorectal cancer. CILP2 was barely reported with clinical features of tumors.Materials and methods: Clinical information and RNA-seq data were derived from the TCGA colorectal carcinoma cohort. CILP2 expression at mRNA level was estimated by bioinformatical analysis of TCGA cases. Tissue microarray (TMA) was constructed containing paraffin-embedded 64 pairs of CRC and matched adjacent normal tissues. The expression at the protein level was detected in 64 pairs of CRC and matched adjacent normal tissues by immunohistochemical analysis. CILP2 expression level and its clinical value were estimated by bioinformatical analysis with linear and logistic regression. Survival analysis was performed between high and low groups of CILP2 expression by Cox regression analysis, and the P-value was calculated by the log-rank test. Kaplan-Meier curves were tested by the log-rank test. Results: CILP2 was statistically significant higher expressed in the colorectal cancer tissues when compared with paired adjacent normal tissues in the TCGA cohort (P<0.001) and in the TMA cohort (P=0.001). Also, CILP2 high-expression was strongly correlated with T3/4 stage (P=0.001), N1/2/3 stage (P=0.005), M1 stage (P=0.048), and higher clinical stage (UICC 2010 stage) (P<0.001) in TCGA cohort, and also positively associated with T3/4 stage (P=0.022) and higher clinical stage (UICC 2010 stage) (P=0.03) in TMA cohort. Furthermore, CILP2 overexpression predicted poor prognosis and could be as an independent prognostic factor (P=0.003).Conclusion: We revealed that CILP2 is associated with advanced stages and could play a role as an independent predictor of poor survival in colorectal cancer.

show abstract

Expression of Foxp3 and interleukin‑7 receptor and clinicopathological characteristics of patients with diffuse large B‑cell lymphoma

Cited by 11 publications

References 37 publications

CILP2 overexpression correlates with tumor progression and poor prognosis in patients with colorectal cancer in the study of The Cancer Genome Atlas (TCGA) and our cohort analysis

CILP2 overexpression correlates with tumor progression and poor prognosis in patients with colorectal cancer in the study of The Cancer Genome Atlas (TCGA) and our cohort analysis

CILP2 overexpression predicts poor prognosis in colorectal cancer

CILP2 overexpression correlates with tumor progression and predicts poor outcome in patients with colorectal cancer

Contact Info

Product

Resources

About